POSTER SESSION I & WELCOME RECEPTION

Sunday, October 23, 2016: 6:30 PM - 8:30 PM
Bayshore Ballroom ABC, Lobby Level (Westin Bayshore Vancouver)
PS 1-50

COST-EFFECTIVENESS OF LUNG CANCER SCREENING WITH LOW DOSE COMPUTED TOMOGRAPHY IN BRITISH COLUMBIA
Tania Conte, RN, MSc1, Mohsen Sadatsafavi1 and Stirling Bryan, PhD2, (1)Centre for Clinical Epidemiology & Evaluation, Vancouver, BC, Canada, (2)University of British Columbia; Centre for Clinical Epidemiology & Evaluation, Vancouver, BC, Canada
PS 1-1

EARLY INITIATION OF HAART TO FORESTALL AIDS-RELATED LYMPHOMA IN SOUTH AFRICA: A COST-EFFECTIVENESS ANALYSIS
Irene Kyomugisha, MSc1, Beate Sander, PhD2, Farai Nyabadza, PhD1, Cang Hui, PhD1 and Akin Abayomi, PhD3, (1)Stellenbosch University, Stellenbosch, South Africa, (2)Public Health Ontario, Toronto, ON, Canada, (3)Stellenbosch University, Cape Town, South Africa
PS 1-2

HEALTH ECONOMIC EVALUATION OF DISEASE MODIFYING MEDICINES USED FOR MULTIPLE SCLEROSIS
Vida Hamidi, Ph.D, Elisabeth Couto, PhD and Marianne Klemp, MD, PhD, Norwegian Institute of Public Health, Oslo, Norway
PS 1-3

USING COST-EFFECTIVENESS ANALYSIS TO DETERMINE A THRESHOLD FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS
Phuc Le, PhD, MPH, Medicine Institute Cleveland Clinic, Cleveland, OH and Michael Rothberg, MD, MPH, Cleveland Clinic, Cleveland, OH
PS 1-4

COST-EFFECTIVENESS ANALYSIS OF DRUGS FOR CHRONIC HEPATITIS C INFECTION: INFORMING ON LISTING DECISIONS OF INTERFERON-FREE DIRECT-ACTING ANTIVIRAL REGIMENS IN CANADA
William W. L. Wong, PhD1, Karen M. Lee, MA2, Sumeet Singh, BScPhm, MSc2 and Murray Krahn, MD, MSc, FRCPC3, (1)School of Pharmacy, University of Waterloo, Kitchener, ON, Canada, (2)Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada, (3)Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada
PS 1-6

TEN-YEAR TRENDS IN DIRECT COSTS OF ASTHMA: A POPULATION-BASED STUDY
Hamid Tavakoli, MD, MSc, University of British Colombia, Department of Medicine,Division of Respiratory Medicine, Vancouver, BC, Canada, J Mark FitzGerald, MD, FACP., UBC , Department of Medicine,The Lung Centre, Vancouver, BC, Canada, Wenjia Chen, PhD Candidate, University of British Columbia,Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, Larry D. Lynd, PhD, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, Tetyana Kendzerska, MD, MSc, PhD, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, Shawn Aaron, MD, FRCPC, University of Ottawa, Division Director- Respirology, Ottawa, ON, Canada, Andrea Gershon, MD, M.Sc., Sunnybrook Health Sciences Centre, Toronto, ON, Canada, Carlo Marra, PhD, Memorial University, St. John's, NF, Canada and Mohsen Sadatsafavi, MD, PhD, UBC, Department of Medicine, Vancouver, BC, Canada
PS 1-7

SYSTEMATIC OVERVIEW OF DECISION-ANALYTIC MODELING STUDIES IN IODINE DEFICIENCY RELATED DISEASES
Ursula Rochau, MD, MSc, UMIT, Dept. of Public Health, Health Services Research & HTA / ONCOTYROL - Center for Personalized Cancer Medicine, Area 4 HTA and Bioinformatics, Hall i. T./Innsbruck, Austria, Marie Schoenhensch, BSc, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i. T., Austria, Vjollca Qerimi, MPharm, Institute of Public Health, Medical Decision Making and HTA, Department of Public Health, Health Services Research and HTA, UMIT - University for Health Sciences, Medical Informatics and Technology / Faculty of Pharmacy, University of Skopje, Macedonia, Hall in Tyrol, Austria, Igor Stojkov, MPharm, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, Hall i. T., Austria, Robin Peeters, MD, PhD, Thyroid Center, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands, Rodrigo Moreno-Reyes, MD, PhD, Department of Nuclear Medicine, Hospital Erasme, Université Libre de Bruxelles, Belgium, Brussels, Belgium, Henry Völzke, MD, Institute for Community Medicine, University Medicine Greifswald, Germany, Greifswald, Germany, Uwe Siebert, MD, MPH, MSc, ScD, UMIT, Dept. of Public Health, Health Services Research & HTA / Harvard Univ., Dept. Health Policy & Management, Institute for Technology Assessment / Oncotyrol - Center for Personalized Cancer Medicine, Hall in Tirol (Austria) / Boston (USA), Austria and Beate Jahn, PhD, Institute of Public Health, Medical Decision Making and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, Hall in Tyrol, Austria
PS 1-8

ESTIMATING THE HEALTHCARE COSTS ATTRIBUTABLE TO WEST NILE VIRUS: A POPULATION-BASED MATCHED COHORT STUDY IN ONTARIO, CANADA
Beate Sander, PhD1, Emily Shing1, John Wang, MSc1, Man Wah Yeung2, Jonathan Gubbay3, Erik Kristjanson3, Alex Marchand-Austin3, Stephen Moore1, Curtis Russell, PhD1, Doug Sider1 and Mark Nelder, PhD1, (1)Public Health Ontario, Toronto, ON, Canada, (2)Health Quality Ontario, Toronto, ON, Canada, (3)Public Health Ontario Laboratory, Toronto, ON, Canada
PS 1-9

A MODEL FOR REAL TIME ACTIVITY BASED COSTING IN ACUTE TRAUMA CARE
Larissa Roux, MD MPH PhD, T6 Health Systems, Vancouver, BC, Canada, Maureen Brennan, CHIM, CAISS, PMP, Vancouver, BC, Canada, Jill Van Den Bos, ASA, MAAA, MA, Milliman, Denver, CO, S. Morad Hameed, MD MPH, T6 Health Systems, Chestnut Hill, MA and Mitchell Jay Cohen, MD, FACS, University of Colorado Department of Surgery, Denver, CO
PS 1-10

CORNEAL CROSS-LINKING VERSUS PENETRATING KERATOPLASTY IN THE TREATMENT OF KERATOCONUS: A COST-EFFECTIVENESS ANALYSIS
Victoria Leung, MD1, Petros Pechlivanoglou, MSc, PhD2, Hall Chew, MD FRCSC1, Murray D. Krahn, MD, MSc3 and Wendy Hatch, OD, MSc1, (1)Department of Ophthalmology and Vision Sciences, Toronto, ON, Canada, (2)Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, (3)University of Toronto and University Health Network, Toronto General Research Institute, Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada
PS 1-11

MODELING THE COST-EFFECTIVENESS OF A HYPOTHETICAL FAMILY PLANNING INTERVENTION DURING A ZIKA OUTBREAK IN THE UNITED STATES
Rui Li, PhD, Katharine Simmons, MD, Jeanne Bertolli, PhD, Lisa Romero, DrPH, Lisa Koonin, DrPH, Denise Jamieson, MD, Wanda Barfield, MD, Cynthia Moore, MD, Cara Mai, DrPH, Shanna Cox, MSPH, Lauren Korhonen, MSPH and Scott Grosse, PhD, Centers for Disease Control and Prevention, Atlanta, GA
PS 1-12

PUBLICALLY ACCESSIBLE SIMULATIONS TO EXPLORE THE COST-EFFECTIVENESS OF PHARMACOGENOMICS IMPLEMENTATIONS
Josh Peterson, MD, MPH1, Shawn Garbett, BSE2, Kathleen Doherty, BA3, Jonathan Schildcrout, PhD1, Catherine Smith, BA3 and John Graves, PhD1, (1)Vanderbilt University School of Medicine, Nashville, TN, (2)Vanderbilt University, Nashville, TN, (3)Vanderbilt University Medical Center, Nashville, TN
PS 1-13

BUDGET IMPACT ANALYSIS FOR THE TREATMENT OF GENOTYPE 1 CHRONIC HEPATITIS C IN GERMANY WITH OMBITASVIR / PARITAPREVIR / RITONAVIR AND DASABUVIR
Beate Jahn, PhD1, Gaby Sroczynski, MPH, Dr.PH1, Annette Conrads-Frank, PhD1, Heike Froehlich, Dr.2, Birgitta Dietz, MD, PHD3, Jennifer Samp, PHARMD, MS4, Stefan Zeuzem, Prof., Dr.5 and Uwe Siebert, MD, MPH, MSc, ScD6, (1)Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, (2)AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, (3)AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, (4)AbbVie Inc., North Chicago, IL, (5)University Hospital Frankfurt, Frankfurt, Germany, (6)UMIT, Dept. of Public Health, Health Services Research and Health Technology, Hall in Tirol, Austria
PS 1-14

DEMENTIA ECONOMIC MODELLING: DISEASE PREVENTION, DIAGNOSIS AND DISEASE PROGRESSION
Penny Breeze, PhD1, Praveen Thokala, PhD2, Alan Brennan, MSc, PhD3, Louise Lafortune4 and Carol Brayne4, (1)Sheffield, United Kingdom, (2)University of Sheffield, Sheffield, United Kingdom, (3)Health Economics and Decision Science (HEDS), School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, United Kingdom, (4)University of Cambridge, Cambridge, United Kingdom
PS 1-15

A DECISION MODEL TO ESTIMATE UNINTENDED PREGNANCIES AVERTED AND COST SAVINGS FROM THE PROVISION OF FREE LONG-ACTING REVERSIBLE CONTRACEPTIVES
Marcelo Perraillon, PhD, University of Colorado Anschutz Medical Campus, Aurora, CO and Melanie Whittington, MA, Aurora, CO
PS 1-16

IS A DECISION AID DESIGNED TO FACILITATE SHARED DECISION MAKING ABOUT ADVANCE CARE PLANS FEASIBLE TO USE IN OUTPATIENT CLINICS? RESULTS FROM FEASIBILITY TESTING OF INFORMEDTOGETHER
Negin Hajizadeh, MD, MPH1, Melissa Basile, PhD2, Johanna Andrews, MPH2, Sonia Jacome, MS2, Lauren McCullagh2 and Michael Diefenbach, PhD1, (1)Hofstra Northwell School of Medicine and Northwell Health, Manhasset, NY, (2)Northwell Health, Manhasset, NY
PS 1-17

PROVIDER EXPERIENCE USING A DECISION SUPPORT TOOL FOR PNEUMONIA: A MIXED METHODS STUDY
Barbara Jones, MD, MSc1, Herman Post2, John Holmen2, Caroline Vines3, David Collingridge4, Jorie Butler5, Charlene Weir, PhD6, Peter Haug2 and Nathan Dean4, (1)University of Utah, Salt Lake City VA Health System and SLC "IDEAS" Center of Innovation, Salt Lake City, UT, (2)Homer Warner Center for Informatics, Murray, UT, (3)Murray, UT, (4)Intermountain Healthcare, Murray, UT, (5)University of Utah, SLC VA Health System, IDEAS, Salt Lake City, UT, (6)Department of Biomedical Informatics, School of Medicine, University of Utah, Salt Lake City, UT
PS 1-18

PATIENT INFORMATION AND DECISION-MAKING IN CONGENITAL AORTIC AND PULMONARY VALVE SURGERY: PHYSICIAN OPINION
Jonathan R.G. Etnel1, Willem A. Helbing, MD, PhD2, Jolien W. Roos-Hesselink, MD, PhD3, Ad J.J.C. Bogers, MD, PhD1 and Johanna Takkenberg, MD, PhD1, (1)Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands, (2)Department of Pediatrics, Division of Cardiology, Erasmus University Medical Center - Sophia Childrens Hospital, Rotterdam, Netherlands, (3)Department of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands
PS 1-19

PERSPECTIVES OF SURROGATE DECISION MAKERS ON PROGNOSIS AFTER BRAIN HEMORRHAGE
Darin Zahuranec, MD, MS1, Renee Anspach, PhD2, Meghan Roney, MPH1, Andrea Fuhrel-Forbis, MA1, Bradford Thompson, MD3, Panayiotis Varelas, MD, PhD4, Lewis Morgenstern, MD5 and Angela Fagerlin, PhD6, (1)University of Michigan Center for Bioethics and Social Sciences in Medicine, Ann Arbor, MI, (2)University of Michigan College of Literature, Science and the Arts, Ann Arbor, MI, (3)The Warren Alpert Medical School of Brown University, Providence, RI, (4)Henry Ford Hospital, Detroit, MI, (5)University of Michigan, Ann Arbor, MI, (6)University of Utah, Department of Population Health Sciences, Salt Lake City, UT
PS 1-20

EFFECT OF COUNSELING QUALITY ON PSYCHOLOGICAL OUTCOMES AFTER SECOND-TRIMESTER TERMINATION FOR PREGNANCY COMPLICATIONS
Jennifer Kerns, MD MPH, Biftu Mengesha, MD, Arianna Cassidy, MD, Geffan Pearlson, BA and Miriam Kuppermann, PhD, MPH, University of California, San Francisco, Department of Obstetrics, Gynecology & Reproductive Sciences, San Francisco, CA
PS 1-21

IMPROVING UNDERSTANDING OF TEST RESULTS BY SUBSTITUTING (NOT ADDING) GOAL RANGES
Aaron Scherer, PhD1, Holly O. Witteman, PhD2, Jacob Solomon, PhD3, Angela Fagerlin, PhD4, Nicole L. Exe, MPH3 and Brian J. Zikmund-Fisher, PhD3, (1)University of Iowa, Iowa City, IA, (2)Laval University, Quebec City, QC, Canada, (3)University of Michigan, Ann Arbor, MI, (4)University of Utah, Department of Population Health Sciences, Salt Lake City, UT
PS 1-22

HOW DO PATIENTS INTERPRET VARIABILITY AND SLOPE IN BLOOD PRESSURE DATA VISUALIZATIONS?
Victoria A. Shaffer, PhD1, KD Valentine, MS1, Pete Wegier, PhD1, Jeffery Belden, MD1, Shannon Canfield, MPH1, Sonal Patil, MD1, Mihail Popescu, PhD1, Linsey Steege, PhD2, Akshay Jain, MS1, Andrew Hathaway, BS1, Michael LeFevre, PhD1 and Richelle Koopman, MD, MS1, (1)University of Missouri, Columbia, MO, (2)University of Wisconsin, Madison, WI
PS 1-23

PARENTAL PERCEPTIONS OF WEIGHT-RELATED INFORMATION: HOW PROVIDER-PARENT COMMUNICATION INFLUENCES DECISION MAKING AND CHILD HEALTH OUTCOMES
Gwen Jacobsohn, PhD, University of Wisconsin-Madison, Dept. of Family Medicine & Community Health, Madison, WI and Kristen Harrison, PhD, University of Michigan, Dept. of Communication Studies, Ann Arbor, MI
PS 1-24

MEASURING THE SHARED DECISION MAKING PROCESS: A SYSTEMATIC REVIEW OF INSTRUMENTS AND THEIR PSYCHOMETRIC PROPERTIES
Fania R. Gärtner, PhD1, Hanna Bomhof-Rordink, MSc2, Ian Smith, MSC2, Anne M. Stiggelbout, PhD3 and Arwen H. Pieterse, PhD3, (1)Leiden University Medical Centre, Leiden, the Netherlands, Leiden, Netherlands, (2)Leiden University Medical Center Department of Medical Decision making, Leiden, Netherlands, (3)Leiden University Medical Center, Leiden, Netherlands
PS 1-25

REVISITING AN SMDM CALL FOR SHARED DECISION-MAKING IN ADVANCED HEART FAILURE
Estevan Delgado, BA1, Kelly MacKenzie, BA2, Savitri Fedson, MD2, Kristin Kostick, PhD, MFA2 and Jennifer Blumenthal-Barby, PhD, MA1, (1)Center for Medical Ethics and Health Policy: Baylor College of Medicine, Houston, TX, (2)Baylor College of Medicine Center for Medical Ethics and Health Policy, Houston, TX
PS 1-26

PATIENT EMPOWERMENT IN HEALTH CARE ENGAGEMENT: A FOCUS ON VULNERABLE POPULATIONS
Rajvir Shahi, BSc., M.D., Ghazaleh Kiani, BSc., Syune Hakobyan, M.D, MHSC, Tyler Raycraft, BSc., Arshia Alimohammadi, BSc., Yashna Bhutani, BSc., BSN and Brian Conway, M.D., FRCPC, Vancouver ID Research and Care Centre Society, Vancouver, BC, Canada
PS 1-27

UTILIZATION OF CONTINUOUS “SPINNERS” TO COMMUNICATE RISK
Rachel Eyler, PharmD, University of Connecticut School of Pharmacy, Storrs, CT, Sara Cordes, PhD, Boston College, Chestnut Hill, MA and Liana Fraenkel, MD, MPH, Yale University, West Haven, CT
PS 1-28

ACTIVE SURVEILLANCE VERSUS INITIAL NEPHRON-SPARING TREATMENT FOR SMALL RENAL TUMORS: A DECISION ANALYSIS
Stella Kang, MD, MS1, William Huang, MD1, Pari V. Pandharipande, MD, MPH2 and R. Scott Braithwaite, MD, MSc, FACP1, (1)New York University School of Medicine, New York, NY, (2)Massachusetts General Hospital - Institute for Technology Assessment, Boston, MA
PS 1-29

TARGETED SCREENING FOR CANCER: TAILORING POLICY TO BIOLOGICAL MECHANISM
Roman Gulati, MS1, Heather Cheng, MD2, Paul Lange, MD2, Peter Nelson, MD2 and Ruth Etzioni, PhD1, (1)Fred Hutchinson Cancer Research Center, Seattle, WA, (2)University of Washington, Seattle, WA
PS 1-30

IDENTIFYING RESOURCE USE AND CAPACITY CONSTRAINT TRADEOFFS ASSOCIATED WITH IMPLEMENTING NEW SCREENING GUIDELINES IN NORWAY
Emily A. Burger, PhD1, Kine Pedersen, MPhil2, Stephen Sy, MS1, Ivar Sønbø Kristiansen, MD, PhD, MPH2 and Jane J. Kim, PhD1, (1)Harvard T.H. Chan School of Public Health, Boston, MA, (2)Department of Health Management and Health Economics, University of Oslo, Oslo, Norway
PS 1-32

USING AN INSTRUMENTAL VARIABLE TO DETERMINE THE CAUSAL EFFECT OF OPPORTUNISTIC MAMMOGRAPHY ON BREAST CANCER MORTALITY
Mette Lise Lousdal1, Tim L. Lash2, M. Alan Brookhart3, Ivar S. Kristiansen4, Mette Kalager4, Peter Vedsted1 and Henrik Støvring1, (1)Aarhus University, Department of Public Health, Aarhus, Denmark, (2)Emory University, Rollins School of Public Health and Winship Cancer Institute, Atlanta, GA, (3)University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, NC, (4)Oslo University, Department of Health Management and Health Economics, Oslo, Norway
PS 1-33

EXAMINING THE IMPORTANCE OF UNCERTAINTY AROUND AMERICAN COLLEGE OF MEDICAL GENETICS (ACMG) RECOMMENDATIONS FOR NEWBORN SCREENING FOR CITRULLENIMIA TYPE 2 (CIT II)
Ahmad Alharbi, MS and Brian Rittenhouse, MS, PhD, MCPHS University, Boston, MA
PS 1-34

PRIMARY CARE PHYSICIANS' LUNG CANCER SCREENING PRACTICES: COMPARISONS BEFORE AND AFTER THE CENTERS FOR MEDICARE & MEDICAID'S NATIONAL COVERAGE DETERMINATION
Lisa M. Lowenstein, PhD, MPH, Viola B. Leal, MPH, Vincent F. Richards, Andrea P. Hempstead, Lewis E. Foxhall, MD and Robert J. Volk, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX
PS 1-35

THE IMPACT OF TIME TO DIAGNOSTIC ASSESSMENT ON SCREENING EFFICACY
Carolyn Rutter, PhD, RAND, Santa Monica, CA, Jane J. Kim, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, Anna Tosteson, Dartmouth, xxx, VT, Reinier Meester, Erasmus MC, University Medical Center, Department of Public Health, Rotterdam, Netherlands, Amy Trentham-Dietz, PhD, University of Wisconsin, Madison, WI, Brian Sprague, xxx, VT, Natasha K. Stout, Ph.D., Department of Population Medicine, Boston, MA, Oguzhan Alagoz, PhD, University of Wisconsin-Madison, Madison, WI and Ann G. Zauber, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY
PS 1-36

SMOKING HISTORY AND ELIGIBILITY FOR LUNG CANCER SCREENING: HOW CLOSE IS CLOSE ENOUGH?
Robert J. Volk, Tito R. Mendoza and Therese B. Bevers, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
PS1-37

SCREENING FOR MELANOMA IN MEN: A COST-EFFECTIVENESS ANALYSIS
Jamie Jarmul, BS, UNC School of Medicine, Chapel Hill, NC, Adewole Adamson, MD, MPP, UNC Department of Dermatology, Chapel Hill, NC and Michael Pignone, MD, MPH, UT-Austin Dell Medical School, Austin, TX
PS 1-38

PERSONALIZING LUNG CANCER SCREENING RECOMMENDATIONS ACROSS THE SPECTRUM OF BENEFIT
Tanner J. Caverly, MD1, Pianpian Cao, MPH2, Rodney Hayward, MD3 and Rafael Meza, PhD2, (1)Ann Arbor VA Center for Clinical Management Research, Ann Arbor, MI, (2)University of Michigan School of Public Health, Ann Arbor, MI, (3)Ann Arbor VA HSR&D Center for Innovation, Ann Arbor, MI
PS 1-39

UNDERSTANDING THE EFFECTS OF LEAD TIME AND OVERDIAGNOSIS IN MAMMOGRAPHY SCREENING: THE SCREENING ILLUSTRATOR
Mette Holm Møller1, Mette Lise Lousdal1, Ivar S. Kristiansen2, Mette Kalager2, Torbjørn Wisløff3 and Henrik Støvring1, (1)Aarhus University, Department of Public Health, Aarhus, Denmark, (2)Oslo University, Department of Health Management and Health Economics, Oslo, Norway, (3)Norwegian Institute of Public Health, Oslo, Norway
PS 1-40

EFFECT OF A LUNG CANCER SCREENING DECISION AID ON KNOWLEDGE OF SCREENING HARMS AND SCREENING PREFERENCE IN PRIMARY CARE PATIENTS
Daniel S. Reuland, MD, MPH1, Alison Brenner, PhD2, Laura Cubillos, MPH3, Russel Harris, MD MPH4, Bailey Minish3 and Michael Pignone, MD, MPH1, (1)University of North Carolina School of Medicine, Chapel Hill, NC, (2)Cecil G Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, (3)University of North Carolina at Chapel Hill, Chapel Hill, NC, NC, (4)Cecil G Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC
PS 1-41

USING SOCIAL NETWORK ANALYSIS TO UNDERSTAND PERIOPERATIVE STAFF TOPOLOGY AT A HIGH-VOLUME SPECIALTY HOSPITAL
Nathaniel Hupert, MD, MPH1, Abigail Schmucker, BA2, Mayu Sasaki, MPH2, Ting-Jung Pan, MPH3, Meghan Kirksey, MD, PhD3, David Grace, PhD3, Stephen Lyman, PhD3, Steven Magid, MD2 and Scott DeNegre, PhD3, (1)Weill Medical College, Cornell University, New York, NY, (2)Quality Research Center, Hospital for Special Surgery, New York, NY, (3)Hospital for Special Surgery, New York, NY
PS 1-42

PATTERNS OF CARE IN TREATING CHILDHOOD NEUROBLASTOMA: EVIDENCE FROM A POPULATION LEVEL STUDY IN THE UNITED STATES
Diarmuid Coughlan, PhD MSc., Matthew Gianferante, MD and Lynne Harlan, PhD, National Cancer Institute, Bethesda, MD
PS 1-43

MECHANISMS OF CLINICIAN-ATTRIBUTABLE VARIATION IN HEALTH CARE: A PILOT STUDY
Kuldeep Yadav, BA1, Michael Josephs, BA2, Nicole Gabler, PhD, MPH3, Michael Detsky, MD, MSHP4, Scott Halpern, MD, PhD1 and Joanna Hart, MD, MSHP2, (1)Palliative and Advanced Illness Research (PAIR) Center, University of Pennsylvania, Philadelphia, PA, (2)Fostering Improvements in End-of-Life Decision Science (FIELDS) Program, University of Pennsylvania, Philadelphia, PA, (3)Fostering Improvement in End-of-Life Decision Science (FIELDS) Program, University of Pennsylvania, Philadelphia, PA, (4)Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
PS 1-44

THE CONSEQUENCES OF MEDICAL ERRORS ON HEALTHCARE PROVIDERS: THE CONCEPT OF SECOND VICTIM
Victoria Koné, MD, Public health unit: Risk Management and Quality of Care, Paris Centre University Hospital Group, AP-HP, Paris, France, Gwenaelle Vidal-Trecan, MD, PhD, Department of Public Health, Faculty of Medicine, Paris Descartes University, Sorbonne Paris Cité, Paris, France., Paris, France and Clément Duret, MD, Public health ward: Risk Management and Quality of Care, Paris Centre University Hospital Group, AP-HP, France, Paris, France
PS 1-45

END-AVERSION IN TIME TRADE-OFF VALUATION?
Kim Rand-Hendriksen, PhD, Cand.Psychol, Akershus University Hospital, Health Services Research Centre, Loerenskog, Norway, Liv Ariane Augestad, MD, PhD, University of Oslo, Oslo, Norway and Mathias Barra, PhD, Health Services Research Centre, Akershus University Hospital, Loerenskog, Norway
PS 1-46

HEALTH UTILITY ESTIMATES AMONG PERSONS LIVING WITH HIV IN THE U.S. – IMPLICATIONS FOR COST-EFFECTIVENESS MODELING AND FUTURE RESEARCH NEEDS
Hilary Whitham, PhD, MPH1, Miriam Kuppermann, PhD, MPH2, Ram K. Shrestha, PhD1, Angela Hutchinson, PhD, MPH1, Birgit Grund, PhD3, Luke Shouse, MD1 and Stephanie Sansom, PhD1, (1)Centers for Disease Control and Prevention, Atlanta, GA, (2)University of California, San Francisco, Department of Obstetrics, Gynecology & Reproductive Sciences, San Francisco, CA, (3)School of Statistics, University of Minnesota, Minneapolis, MN
PS 1-47

GETTING PATIENTS IN THE DOOR: MEDICAL APPOINTMENT REMINDER PREFERENCES
Trisha Crutchfield, MHA, MSIS, UNC Center for Health Promotion and DIsease Prevention, The University of North Carolina at Chapel Hill, Chapel Hill, NC and Christine E. Kistler, MD, MASc, Department of Family Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC
PS 1-48

HOW DO WOMEN VALUE TRADE-OFFS IN MATERNAL-FETAL MORBIDITY AND MORTALITY?
Brownsyne Tucker Edmonds, MD, MPH, MS1, Fatima McKenzie, MS1, Janet Panoch, MA2, Stephen M. Downs, MD, MS3 and Aaron Carroll, MD, MS4, (1)Indiana University School of Medicine, Indianapolis, IN, (2)IU School of Medicine, Indianapolis, IN, (3)Children's Health Services, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, (4)Pediatric and Adolescent Comparative Effectiveness Research Indiana University School of Medicine, Indianapolis, IN
PS 1-49

DEVELOPMENT OF A CONCEPTUAL CROSSWALK BETWEEN RESIDENT ASSESSMENT INSTRUMENTS AND THE EQ-5D-5L
Mark Oremus, PhD1, Micaela Jantzi1, Feng Xie, PhD2 and John Hirdes, PhD1, (1)University of Waterloo, Waterloo, ON, Canada, (2)McMaster University, Hamilton, ON, Canada
PS 1-51

HEALTH UTILITIES OF RARE HERITABLE DISORDERS: APPROACHES FOR HEALTH STATE DESCRIPTIONS AND MEASURING SPILLOVER EFFECTS ON FAMILY MEMBERS
John S. Richardson, MPH, University of Michigan, Ann Arbor, MI, Eve Wittenberg, MPP, PhD, Harvard School of Public Health, Boston, MA and Lisa A. Prosser, MS, PhD, University of Michigan, Child Health Evaluation and Research Center, Ann Arbor, MI
PS 1-52

HEALTH LITERACY AND LOGICAL INCONSISTENCIES IN VALUATIONS OF HYPOTHETICAL HEALTH STATES: RESULTS FROM THE CANADIAN EQ-5D-5L VALUATION STUDY
Fatima Al Sayah, PhD1, Jeffrey A Johnson, PhD1, Arto Ohinmaa, PhD1, Feng Xie, PhD2 and Nick Bansback, PhD3, (1)School of Public Health, University of Alberta, Edmonton, AB, Canada, (2)McMaster University, Hamilton, ON, Canada, (3)University of British Columbia; Centre for Clinical Epidemiology and Evaluation; Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada
PS 1-53

ESTIMATING A CHINESE EQ-5D-5L VALUE SET USING NONLINEAR MODELS
Nan Luo, PhD, National University of Singapore, Singapore, Singapore, Gordon Liu, PhD, Peking University, Beijing, China, Minghui Li, MSc, University of South Carolina, Columbia, SC and Kim Rand-Hendriksen, PhD, Cand.Psychol, University of Oslo, Oslo, Norway
PS 1-54

AN INVESTIGATION OF ATTRIBUTE NON-ATTENDANCE IN CHOICE EXPERIMENTS CONTAINING DISEASE LABELS
Helen McTaggart-Cowan, Ph.D.1, Dean A. Regier, PhD2 and Stuart J. Peacock, D.Phil.1, (1)Canadian Centre for Applied Research in Cancer Control, Vancouver, BC, Canada, (2)Canadian Centre for Applied Research in Cancer Control, BC Cancer Agency, Vancouver, BC, Canada
PS 1-55

WHAT DO YOU BELIEVE? AN ONLINE TOOL FOR COST-EFFECTIVENESS ANALYSIS OF CIRCULATING TUMOR CELL DETECTION BASED ON USER BELIEFS
Sofie Berghuis, MSc, Hendrik Koffijberg, PhD and Maarten J. IJzerman, PhD, University of Twente, Enschede, Netherlands
PS 1-56

BROADENING ECONOMIC EVALUATION - A CASE STUDY OF DEMENTIA
Thaison Tong, MSc1, John Brazier, BA, MSc, PhD2, Penny Breeze, PhD3 and Praveen Thokala, PhD1, (1)University of Sheffield, Sheffield, United Kingdom, (2)The University of Sheffield, Sheffield, United Kingdom, (3)Sheffield, United Kingdom
PS 1-57

R IN HEALTH DECISION SCIENCES: A SCOPING REVIEW
Hawre Jalal, MD, PhD, University of Pittsburgh, Pittsburgh, PA, Petros Pechlivanoglou, MSc, PhD, Toronto, ON, Canada, Eline Elinekrijkamp, MSc, Amsterdam, Netherlands, Fernando Alarid-Escudero, MS, PhD Candidate, Division of Health Policy and Management, University of Minnesota, Minneapolis, MN, Eva A. Enns, MS, PhD, University of Minnesota, Minneapolis, MN and M.G. Myriam Hunink, MD, PhD, Center for Health Decision Science, Harvard T.H.Chan School of Public Health, Boston, MA
PS 1-58

DTREE: AN OPEN SOURCE TOOL FOR BUILDING DECISION TREES AND COST-EFFECTIVENESS ANALYSES
Hawre Jalal, MD, PhD, University of Pittsburgh, Pittsburgh, PA, Anne Cross, Pittsburgh, PA, Fernando Alarid-Escudero, MS, PhD Candidate, Division of Health Policy and Management, University of Minnesota, Minneapolis, MN and M.G. Myriam Hunink, MD, PhD, Center for Health Decision Science, Harvard T.H.Chan School of Public Health, Boston, MA
PS 1-59

TOWARD A BROADER VALUE FRAMEWORK FOR HEALTH TECHNOLOGY ASSESSMENT: EXPANDED COST-EFFECTIVENESS ANALYSIS
Louis Garrison, PhD, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA and Adrian Towse, MA, MPhil, Office of Health Economics, London, United Kingdom
PS 1-60

PROBABILISTIC ONE-WAY SENSITIVITY ANALYSIS: A MODIFIED TORNADO DIAGRAM
Isaac Awotwe, BA1, Mike Paulden, PhD2, Peter Hall, PhD3 and Christopher McCabe, PhD1, (1)Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada, (2)University of Alberta, Edmonton, AB, Canada, (3)Edinburgh Cancer Research Centre, University of Edinburgh, UK, Edinburgh, United Kingdom
See more of: 38th Annual North American Meeting of the Society for Medical Decision Making
<< Previous Session | Next Session >>